are also known to affect risk and to confer an adverse prognosis, such as intraductal carcinoma (IDC) 3 or ductal carcinoma 4 histologies, lymphovascular invasion (LVI), 5 and perineural invasion (PNI). 6 Today, with the advent of cancer genomics, there is an ongoing effort to identify, characterize, and validate meaningful molecular biomarkers which may have a profound impact on diagnosis, therapy, and monitoring. With this better understanding, germline and somatic genetic testing may help physicians to choose whether, when and how to treat each individual prostate cancer patient in a more precise manner.
After the development of next-generation sequencing (NGS), the mutational profile of many cancers and their inherited backgrounds are now better recognized. In PCa, genomic studies have shown that the DNA-repair genes play a central role in cancer development, especially in locally advanced, 7 and metastatic disease. 8, 9 These studies demonstrate that up to 20-25% of metastatic castration-resistant prostate cancer (mCRPC) may harbor somatic DNA-repair pathway aberrations, 10 and that approximately 8-12% of recurrent or advanced PCa patients may have deleterious germline abnormalities. 9 The most common examples of these abnormal DNA-repair genes are BRCA2, ATM, CHEK2, and BRCA1. 9 The clinical relevance of these data has increased after the observation that patients who harbor germline and/or somatic DNA-repair mutations may be more sensitive to poly ADP-ribose polymerase (PARP) inhibition. 8, 11, 12 Table 2 . Of the 21 patients testing positive for a deleterious germline mutation, the genes involved were as follows:
and CDH1 (1 patient [5%]). The distribution of these pathogenic germline mutations is shown in Figure 1 .
| Demographic characteristics
Demographic, clinical, and pathological characteristics of this patient cohort are shown in Table 3 . There was no difference in median age at diagnosis between patients with and without deleterious germline mutation (61 vs 63 years, respectively, P = 0.56). Patient race (white vs non-white) was also not associated with presence or absence of a germline mutation (P = 0.48).
| Family history
Neither a prostate cancer family history nor other cancers in the family were statistically associated with a positive germline test. Family history (in a 1st or 2nd degree relative) of prostate cancer was present in 38% of men (eight patients) who had a positive germline test versus 40% of men (52 patients) in the germline-negative group (P = 1.0). A family history of other DNA repair-related cancers (breast, ovarian, uterine, pancreatic, or gastric cancers) was found in 52% (11 patients) and 52% (67 patients) of germline mutation-positive and mutation-negative groups, respectively (P = 1.0). There are no specific prostate cancer NCCN guidelines addressing germline testing. However, the NCCN genetic/familial high-risk assessment: Breast and ovarian cancer guidelines 16 include recommendations for when to consider genetic testing for patients with prostate cancer. The two criteria for testing localized prostate cancer patients for BRCA1/2 mutations are described, as shown in Table 4 . Based on these criteria, 56% of evaluable patients (with available family history, M0 disease, and
Gleason ≥7 at diagnosis) with a positive germline test would have fulfilled criteria for genetic testing, while 20% of patients with a negative germline test would have also fulfilled the same criteria. Despite a trend in favor of germline-positive patients fulfilling these criteria, this association was not statistically significant (P = 0.058). More importantly, this means that 44%
of men with a positive germline test would have been missed if using these NCCN guidelines to select patients for germline genetic testing.
| Clinical and pathologic characteristics
Advanced tumor (T) stage (T3 or T4 disease) was diagnosed in the majority of men in whom the T stage was documented (133 men).
Overall, 61% of patients presented with a T3 or T4 tumor. In patients who had a positive germline test, 62% (N = 13) were diagnosed with a LVI was also significantly associated with a positive germline test.
More than fifty percent of patients (52%, 11/21) who tested positive in their germline test had LVI identified in their biopsy or surgical specimens, whereas LVI was only found in 14% (18/129) of those who tested negative (P = 0.0002). In patients with positive LVI, the prevalence of a germline DRD mutation was 38% (11/29); while in those without LVI, only 8% (10/121) harbored a germline DRD alteration. Another relevant prognostic factor in prostate cancer, perineural invasion (PNI), 20, 21 was not associated with DNA-repair mutations. This pathologic characteristic was seen in 52% and 51% of patients with and without a deleterious germline DRD mutation, respectively (P = 1.0).
Finally, a lower PSA at initial diagnosis was associated with a positive germline test. Median PSA at diagnosis in patients who had a deleterious mutation was 5.5 ng/mL (range 1.3-22.0) versus 8.6 ng/mL (range 0.9-1540) in patients who had a germline-negative test (P = 0.012).
| DISCUSSION
The findings of this study are consistent with the expected prevalence of deleterious germline DRD mutations in men with recurrent or metastatic prostate cancer, as first described by Pritchard et al. 9 In our study, the frequency of deleterious germline mutations in this unselected prostate cancer population was 14%. These mutation rates in recurrent disease 9 are significantly higher than the rates of BRCA1/2 mutations among men with localized prostate cancer. 7, 22 Certainly, our analysis of a broader spectrum of DRD genes (ie, beyond BRCA1 and BRCA2) may have contributed to the higher incidence of these defects seen in our patient population, coupled with the more advanced disease states. Taking into consideration the higher risk of nodal involvement and distant metastasis of BRCA-related PCa, 7 there may be an enrichment of germline DRD mutations in men with advanced disease. This suggests that the likelihood of harboring at least one DNA-repair gene deleterious mutation may be higher in patients with biochemical recurrence after local therapy or in those with (de novo or subsequent) metastatic disease. Strikingly, our study closely corroborates the findings of the Pritchard et al 9 publication.
The four most common germline abnormalities seen in our cohort (BRCA2, ATM, CHEK2, and BRCA1) are the same as the first four in the previously published data. 9 Moreover, the relative distributions of the germline DRD alterations observed here are also similar to the results of the Pritchard data (Table 2 and Figure 1 ). Patients who fulfill NCCN criteria for genetic screening (see Table 4 Not reported 0% (0) 1.6% (2) Presence of intraductal or ductal histology, % (N) 47.6% (10) 11.6% ( to medical oncologists and urologists that germline genetic testing may be warranted. This observation also corroborates a previously published study linking intraductal histology to DRD mutations. 23 That study evaluated patient-derived xenografts of BRCA2 mutation carriers, and showed an prevalence of 42% of intraductal prostate carcinomas in BRCA2 carriers compared with a 25% prevalence in BRCA-negative patients (P = 0.002). Our current findings, coupled with this prior study, suggest that the presence of intraductal features should trigger consideration of prompt genetic counselling and germline testing for DRD mutations.
We have also shown that a lower PSA at initial diagnosis was associated with a positive germline test. Prior studies have shown that high-grade, low-PSA-producing tumors are more likely to be associated with T3-T4 disease, nodal involvement and distant metastases at the time of diagnosis, 24 similar to BRCA1/2-positive prostate cancers. 7 We speculate that patients with high-grade disease which manifests with low PSA levels may be more likely to harbor DNA-repair gene mutations. In addition, some (but not all) studies have reported a non-statistically significant trend between intraductal/ductal prostate cancer histologies and lower median PSA levels. 25, 26 Further study is needed to confirm these preliminary findings.
Our study has several limitations that should be considered when interpreting the results. First, this was a retrospective study. for family counseling as well as therapeutic choices for these patients.
We believe that the presence of one or more of these factors could be added to the family history when considering the decision to request genetic testing and counseling. If these data are confirmed, we would propose that all prostate cancer patients with intraductal/ductal histologies should consider germline genetic testing for DRD mutations. Alternatively, such patients could undergo tumor-based somatic DNA sequencing, followed by germline DNA sequencing in those with a tumoral DRD alteration. Personal history of high-grade prostate cancer (gleason score ≥7) at any age with ≥1 close blood relative with ovarian carcinoma at any age or breast cancer at ≤50 years.
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